FDA Targets Chest Binder Manufacturers Amid Gender-Affirming Care Controversy

The Food and Drug Administration (FDA), under the administration of Donald Trump, has sent warning letters to 11 companies that manufacture chest binders, asserting that these products are "misbranded" medical devices. The companies targeted include TransGuy Supply, the Fluxion, GenderBender, ShapeShifter Apparel, Marli Washington Design, TomboyX, FLAVNT Streetwear, Early to Bed, TOMSCOUT, For Them, and UNTAG (formerly Trans-Missie). The FDA claims these companies failed to register their products as Class I medical devices for the 2026 fiscal year, a requirement that has not been previously enforced.

The Advocate

In the letters, FDA Director Michael J. Hoffmann stated that the binders are classified as devices because they are intended to affect the structure or function of the body, particularly in alleviating gender dysphoria. However, critics argue that chest binders primarily serve aesthetic purposes, similar to shapewear or sports bras, and do not possess medical applications.

The Advocate

The FDA's actions are part of a broader initiative by the Department of Health and Human Services (HHS) to restrict gender-affirming care for minors. Recently, the HHS proposed a ban on such care for individuals under 18 and sought to prevent Medicaid and the Children’s Health Insurance Program (CHIP) from covering these treatments. Although the HHS lacks the legal authority to enforce these proposals, the U.S. House of Representatives has passed bills aimed at banning gender-affirming care for trans youth and restricting Medicaid coverage, which are now pending in the Senate.

The Advocate

The response from advocacy groups has been critical of the FDA's stance. Brandon Wolf, National Press Secretary for the Human Rights Campaign, condemned the administration's actions, stating, "Everyone deserves the freedom to get the healthcare they need... But this administration is trying to control every ounce of trans people's lives." Wolf characterized the FDA's actions as a "deeply un-American obsession with trans people."

The Advocate

Moreover, several prominent medical organizations, including the American Medical Association and the World Health Organization, assert that gender-affirming care is evidence-based and necessary for both adults and minors. They emphasize that no chest binder is specifically designed for minors, nor do any of the companies use child models in their marketing.

The Advocate

The FDA has indicated that further enforcement actions, including import alerts and seizures, may follow if the companies do not address the alleged violations within 15 days. The agency's focus on chest binders aligns with its recent crackdown on gender-affirming care, raising concerns among advocates about the implications for trans individuals seeking necessary support.

The Advocate

• “Everyone deserves the freedom to get the healthcare they need, support their children, and buy products that make them feel good in their own skin,” — Brandon Wolf, National Press Secretary for the Human Rights Campaign

The Advocate

This situation continues to evolve as stakeholders respond to the FDA's actions, highlighting the ongoing debate surrounding gender-affirming care and the rights of trans individuals in the United States.

The Advocate